Oric Pharmaceuticals moved its prostate cancer program toward late-stage testing, planning a registrational Phase 3 program for an investigational PRC2 inhibitor after reporting results from a Phase 1b trial. The company’s update comes with investor reaction suggesting uncertainty around how the team selected and will position its combination strategy. Oric detailed next steps after Phase 1b findings, framing the move as a step into a pivotal program for advanced prostate cancer. But the company’s stock fell in connection with the announcement, with observers highlighting that the combo choice could introduce doubts. The development highlights how oncology companies are using early-phase signals to accelerate into registrational plans—while simultaneously facing scrutiny over the rationale for combinations and expected comparative benefit. For pipeline watchers, the Oric Phase 3 launch decision adds another PRC2-focused candidate to a crowded prostate-cancer development landscape and will set up a key readout on whether early mechanistic hypotheses translate into registrational efficacy.